Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

MLA

Andersen, Jørn, et al. “Tamoxifen for One Year versus Two Years versus 6 Months of Tamoxifen and 6 Months of Megestrol Acetate: A Randomized Comparison in Postmenopausal Patients with High-Risk Breast Cancer (DBCG 89C).” Andersen , J , Kamby , C , Ejlertsen , B , Cold , S , Ewertz , M , Jacobsen , E H , Philip , P , Møller , K A , Jensen , D & Møller , S 2008 , ’ Tamoxifen for One Year versus Two Years versus 6 Months of Tamoxifen and 6 Months of Megestrol Acetate: A Randomized Comparison in Postmenopausal Patients with High-Risk Breast Cancer (DBCG 89C) ’ , Acta Oncologica , Vol. 47 , No. 4 , Pp. 718-724 , 2008. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1322574830&authtype=sso&custid=ns315887.

APA

Andersen, J., Kamby, C., Ejlertsen, B., Cold, S., Ewertz, M., Jacobsen, E. H., Philip, P., Møller, K. A., Jensen, D., & Møller, S. (2008). Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Andersen , J , Kamby , C , Ejlertsen , B , Cold , S , Ewertz , M , Jacobsen , E H , Philip , P , Møller , K A , Jensen , D & Møller , S 2008 , ’ Tamoxifen for One Year versus Two Years versus 6 Months of Tamoxifen and 6 Months of Megestrol Acetate: A Randomized Comparison in Postmenopausal Patients with High-Risk Breast Cancer (DBCG 89C) ’ , Acta Oncologica , Vol. 47 , No. 4 , Pp. 718-724 .

Chicago

Andersen, Jørn, C. Kamby, B. Ejlertsen, Søren Cold, Marianne Ewertz, E.H. Jacobsen, P. Philip, K.A. Møller, D. Jensen, and Susanne Møller. 2008. “Tamoxifen for One Year versus Two Years versus 6 Months of Tamoxifen and 6 Months of Megestrol Acetate: A Randomized Comparison in Postmenopausal Patients with High-Risk Breast Cancer (DBCG 89C).” Andersen , J , Kamby , C , Ejlertsen , B , Cold , S , Ewertz , M , Jacobsen , E H , Philip , P , Møller , K A , Jensen , D & Møller , S 2008 , ’ Tamoxifen for One Year versus Two Years versus 6 Months of Tamoxifen and 6 Months of Megestrol Acetate: A Randomized Comparison in Postmenopausal Patients with High-Risk Breast Cancer (DBCG 89C) ’ , Acta Oncologica , Vol. 47 , No. 4 , Pp. 718-724 . http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1322574830&authtype=sso&custid=ns315887.